Literature DB >> 7811995

Neutralization of heparin activity by neutrophil lactoferrin.

H F Wu1, R L Lundblad, F C Church.   

Abstract

Lactoferrin is a prominent component of neutrophil secondary granules, and its blood concentration is increased in certain inflammatory diseases. In contrast to the well-described biochemical characterization of lactoferrin as an iron-binding protein, its physiologic role in the regulation of inflammation and other host defense mechanisms is unclear. In this report, we provide evidence that lactoferrin has a potent heparin-neutralizing activity during thrombin inhibition by the serine proteinase inhibitors (serpins) antithrombin and heparin co-factor II. Activated neutrophil supernatant, which contains lactoferrin and other heparin-binding proteins, could neutralize the heparin-dependent antithrombin-thrombin inhibition reaction. The addition of lactoferrin to plasma corrected the heparin-induced prolongation of blood plasma coagulation as measured by the activated partial thromboplastin time (aPTT). Treatment of whole blood with specific inflammatory mediators, fMLP, lipopolysaccharide (LPS), and tumor necrosis factor-alpha (TNF-alpha) increased the concentration of both plasma lactoferrin and platelet factor 4 while inhibiting the blood anticoagulant activity of heparin as measured by the aPTT. These results suggest that the prothrombotic sequelae of some inflammatory processes may be partly due to various agonists that release neutrophil lactoferrin, which can then neutralize glycosaminoglycan-dependent serpin-thrombin inhibition reactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7811995

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Structure and biological actions of lactoferrin.

Authors:  J H Nuijens; P H van Berkel; F L Schanbacher
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-07       Impact factor: 2.673

2.  Dendrigraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings.

Authors:  Benjamin Ourri; Jean-Patrick Francoia; Gerald Monard; Jean-Christophe Gris; Julien Leclaire; Laurent Vial
Journal:  ACS Med Chem Lett       Date:  2019-05-08       Impact factor: 4.345

Review 3.  Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations.

Authors:  Sean Garvin; Daniel Fitzgerald; Jochen D Muehlschlegel; Tjörvi E Perry; Amanda A Fox; Stanton K Shernan; Charles D Collard; Sary Aranki; Simon C Body
Journal:  Anesth Analg       Date:  2010-02-08       Impact factor: 5.108

Review 4.  Targeting heparin and heparan sulfate protein interactions.

Authors:  Ryan J Weiss; Jeffrey D Esko; Yitzhak Tor
Journal:  Org Biomol Chem       Date:  2017-06-27       Impact factor: 3.876

5.  N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA.

Authors:  P H van Berkel; M E Geerts; H A van Veen; M Mericskay; H A de Boer; J H Nuijens
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

6.  Lactoferrin regulates the activity of heparin proteoglycan-bound mast cell chymase: characterization of the binding of heparin to lactoferrin.

Authors:  G Pejler
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

Review 7.  Transplantation of Exercise-Induced Extracellular Vesicles as a Promising Therapeutic Approach in Ischemic Stroke.

Authors:  Parsa Alehossein; Maryam Taheri; Pargol Tayefeh Ghahremani; Duaa Dakhlallah; Candice M Brown; Tauheed Ishrat; Sanaz Nasoohi
Journal:  Transl Stroke Res       Date:  2022-05-21       Impact factor: 6.829

8.  Suggestions on leading an academic research laboratory group.

Authors:  Frank C Church
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

9.  Lactoferrin causes IgA and IgG2b isotype switching through betaglycan binding and activation of canonical TGF-β signaling.

Authors:  Y-S Jang; G-Y Seo; J-M Lee; H-Y Seo; H-J Han; S-J Kim; B-R Jin; H-J Kim; S-R Park; K-J Rhee; W-S Kim; P-H Kim
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

10.  Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.

Authors:  Bartlomiej Kalaska; Kamil Kaminski; Emilia Sokolowska; Dominik Czaplicki; Monika Kujdowicz; Krystyna Stalinska; Joanna Bereta; Krzysztof Szczubialka; Dariusz Pawlak; Maria Nowakowska; Andrzej Mogielnicki
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.